Jan 30 (Reuters) – Moderna’s Chief Medical Officer Jacqueline Miller, who led the development of the company’s mRNA-based COVID-19 vaccine Spikevax, will step down effective March 2, the vaccine maker said on Friday.
Miller joined Moderna in 2020 as the therapeutic area head for infectious diseases. Her departure comes at a pivotal moment for the company, which is seeking to plug the revenue gap left by waning demand for COVID products and turn its mRNA platform into a broader, durable franchise.
Over her career, Miller has supported seven novel vaccine approvals for patients ranging from infants to older adults, including Moderna’s Spikevax and respiratory syncytial virus vaccine mRESVIA, according to the company’s website.
Shares of Moderna were down over 2% in premarket trading.
The company named David Berman as Chief Development Officer beginning from March 2. Miller will remain as a consultant to the company to assist with the transition, it added.
Before joining Moderna, Berman served as head of research and development at Immunocore and has previously held senior roles at AstraZeneca and Bristol-Myers Squibb.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shailesh Kuber)
